<DOC>
	<DOCNO>NCT00532857</DOCNO>
	<brief_summary>To evaluate pathologic complete response rate preoperative administration Paclitaxel , Gemcitabine , Trastuzumab ( HerceptinÒ ) ( PGH )</brief_summary>
	<brief_title>Phase II Study Primary Chemotherapy With Paclitaxel , Gemcitabine , Trastuzumab</brief_title>
	<detailed_description>Primary objective : To evaluate pathologic complete response rate preoperative administration Paclitaxel , Gemcitabine , Trastuzumab ( HerceptinÒ ) ( PGH ) Secondary objective : To assess breast conserve rate preoperative chemotherapyTo evaluate clinical response rate , disease free survival ( DFS ) , overall survival ( OS ) To assess safety profile PGH Treatment deliver outpatient setting . Each three-week cycle consist paclitaxel 80 mg/m2 ( day 1 , 8 ) gemcitabine 1200 mg/m2 ( day1 , 8 ) addition trastuzumab , give dose 4 mg/kg IV day 1 first treatment cycle 90 min , subsequently give weekly dose 2 mg/kg 30 min . Patients receive 6 cycle therapy unless evidence response suitable operation ( SD PD ) unacceptable toxicity noncompliance patient protocol requirement . Patients unsuitable op due SD PD , undergo XRT . However , patient still suitable op even SD PD , patient undergo op.Such decision make physician 's discretion institution . Also , even though neither clear evidence disease progression severe toxicity , patient decline treatment , study treatment discontinue . Response document physical examination , sonography and/or chest CT prior treatment every three cycle . Postoperatively within 1-3 week , trastuzumab 6 mg/kg every 3 week x 11 tamoxifen AI 5 year give indicate . Radiation therapy initiate postoperatively 3-4 week accord standard practice guideline .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>All patient must histologically confirm newly diagnose operable breast cancer HER2 positive ( FISH + ) Axillary node positive ( PET cytologically determine node sonography ) and/or tumor size &gt; 5 cm No prior hormonal , chemotherapy radiotherapy allow . No breast operation biopsy make diagnosis allow . Age : 18years old , pregnant pre , postmenopausal woman good performance status ( ECOG 01 ) Adequate hematopoietic function : Absolute granulocyte count ³1500/mm3 , platelet ³100,000/mm3 , Hemoglobin ³ 10 g/mm3 Adequate renal function : Serum creatinine £ 1.5 mg/dl Adequate hepatic function : total bilirubin : £ 1.5 mg/dl , AST/ALT : £ 2 time normal , Alkaline phosphatase : £ 2 time normalAdequate cardiac function : 1. normal nonspecific EKG take within 1 mo enrollment 2 . LVEF ³ 50 % MUGA Echocardiogram take within 1 mo enrollment Normal mental function understand sign consent patient receive hormonal , chemotherapy radiotherapy breast cancer patient underwent surgery breast cancer patient history uncompensated congestive heart failure Patients nodenegative stage IIA ( T2N0 ) breast cancer Patients history cancer situ uterine cervix cancer nonmelanotic skin cancer</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Patients HER2 + stage II/III breast cancer</keyword>
</DOC>